Predictors of ischemic stroke in non-rheumatic atrial fibrillation

International Journal of Cardiology

Volumn 56, Issue 1, 1996, Pages 61-70

  Yoshida, Michiaki ^a   Nakamura, Yasuyuki ^a   Higashikawa, Masahito ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Ischemic stroke; Non rheumatic atrial fibrillation; Predictors

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC HEART DISEASE; RISK FACTOR;

EID: 0030249564     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(96)02726-X     Document Type: Article

References (28)

1. [1] Askey JM, Bernstein S. The management of rheumatic heart disease in relation to systemic arterial embolism. Prog Cardiovasc Dis 1960; 3: 220-232.
2. [2] Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28: 973-977.
3. [3] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: The Framingham Study. Arch Intern Med 1987; 147: 1561-1564.
4. [4] Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982; 306: 1018-1022.
5. [5] Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thrombotic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989; 1: 175-179.
6. [6] The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
7. [7] Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527-539.
8. [8] Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
9. [9] Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
10. [10] Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
11. [11] Kuramoto K, Matsushita, S, Yamanouchi H. Atrial fibrillation as a cause of myocardial and cerebral infarctions. Jpn Circ J 1984; 48: 67-74.
12. [12] Zipes DP. Atrial fibrillation. In: Braunwald E, ed., Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed, Philadelphia: W.B. Saunders Company, 1992: 682-684.
13. [13] Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest 1989; 95(Suppl.1): 140S-155S.
14. [14] Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: The Framingham study. Stroke 1983; 14: 664-667.
15. [15] Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke 1985; 16: 182-188.
16. [16] Peterson P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21: 4-13.
17. [17] The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
18. [18] Naito S, Imataka K, Seko Y, Fujii J. The predictive factors for cerebral infarction in patients with non-rheumatic atrial fibrillation. J Cardiol 1990; 20: 385-390 (in Japanese).
19. [19] Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: The Framingham Study. J Am Med Assoc 1985; 254: 3449-3453.
20. [20] Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. N Engl J Med 1987; 317: 669-674.
21. [21] Moss AJ. Atrial fibrillation and cerebral embolism (Editorial). Arch Neurol 1984; 41: 707.
22. [22] Caplan LR, D'Cruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation and stroke. Ann Neurol 1986; 19: 158-161.
23. [23] Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990; 65: 1112-1116.
24. [24] Tegeler CH, Hart RG, Sherman DG, Quiroga ES, Easton JD. Atrial fibrillation-stroke study (abstr). Stroke 1986; 17: 131.
25. [25] Wiener I. Clinical and echocardiographic correlates of systemic embolization in non-rheumatic atrial fibrillation. Am J Cardiol 1987; 59: 177.
26. [26] The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6-12.
27. [27] Peterson P, Kastrup J, Helweg-Larson S, Boysen G, Godtfredsen J. Risk factors for thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Arch Intern Med 1990; 150: 819-821.
28. [28] Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN, for the V-HeFT VA Co-operative Studies Group. Incidence of Thromboembolic Events in Congestive Heart Failure. Circulation 1993: 87(Suppl. VI): VI94-101.